The requirement for the p53 proline‐rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression

Wild‐type p53 is a tumor suppressor gene which can activate or repress transcription, as well as induce apoptosis. The human p53 proline‐rich domain localized between amino acids 64 and 92 has been reported to be necessary for efficient growth suppression. This study shows that this property mainly results from impaired apoptotic activity. Although deletion of the proline‐rich domain does not affect transactivation of several promoters, such as WAF1, MDM2 and BAX, it does alter transcriptional repression, reactive oxygen species production and sequence‐specific transactivation of the PIG3 gene, and these are activities which affect apoptosis. Whereas gel retardation assays revealed that this domain did not alter in vitro the specific binding to the p53‐responsive element of PIG3, this domain plays a critical role in transactivation from a synthetic promoter containing this element. To explain this discrepancy, evidence is given for a proline‐rich domain‐mediated cellular activation of p53 DNA binding.

[1]  C. Peters,et al.  Potential role for Cathepsin D in p53-dependent tumor suppression and chemosensitivity , 1998, Oncogene.

[2]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[3]  G. Prendergast,et al.  The polyproline region of p53 is required to activate apoptosis but not growth arrest , 1997, Oncogene.

[4]  D. Israeli,et al.  A novel p53‐inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis , 1997, The EMBO journal.

[5]  K. A. McKenna,et al.  p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta. , 1997, Cancer research.

[6]  A. Levine,et al.  A proline-rich motif in p53 is required for transactivation-independent growth arrest as induced by Gas1. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[8]  M. Oren,et al.  p53; from inductive signal to cellular effect. , 1997, Current opinion in genetics & development.

[9]  A. Levine,et al.  Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Lohrum,et al.  Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes. , 1996, Oncogene.

[11]  A. Levine,et al.  Wild-type p53 negatively regulates the expression of a microtubule-associated protein. , 1996, Genes & development.

[12]  C. Prives,et al.  Regulation of Mutant p53 Temperature-sensitive DNA Binding* , 1996, The Journal of Biological Chemistry.

[13]  X. Chen,et al.  p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. , 1996, Genes & development.

[14]  K. Vousden,et al.  Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function , 1996, Molecular and cellular biology.

[15]  C. Prives,et al.  A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis , 1996, Molecular and cellular biology.

[16]  D. Le Paslier,et al.  Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  K. Kinzler,et al.  Genetic determinants of p53-induced apoptosis and growth arrest. , 1996, Genes & development.

[18]  S. Lowe,et al.  Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene‐mediated apoptosis. , 1996, The EMBO journal.

[19]  M. Oren,et al.  p53 in growth control and neoplasia. , 1996, Biochimica et biophysica acta.

[20]  L. Debussche,et al.  A Ras-GTPase-activating protein SH3-domain-binding protein , 1996, Molecular and cellular biology.

[21]  K. Roemer,et al.  p53 transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis. , 1996, Oncogene.

[22]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[23]  M. Oren,et al.  Cell type‐specific inhibition of p53‐mediated apoptosis by mdm2. , 1996, The EMBO journal.

[24]  M. Oren,et al.  Specific loss of apoptotic but not cell‐cycle arrest function in a human tumor derived p53 mutant. , 1996, The EMBO journal.

[25]  K. Vousden,et al.  p53 in signaling checkpoint arrest or apoptosis. , 1996, Current opinion in genetics & development.

[26]  B. Wasylyk,et al.  MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. , 1995, Oncogene.

[27]  E. May,et al.  Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. , 1995, Oncogene.

[28]  K. Kinzler,et al.  p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.

[29]  D. Lane,et al.  Small peptides activate the latent sequence-specific DNA binding function of p53 , 1995, Cell.

[30]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[31]  James Brugarolas,et al.  Radiation-induced cell cycle arrest compromised by p21 deficiency , 1995, Nature.

[32]  S. Korsmeyer,et al.  Bax-Deficient Mice with Lymphoid Hyperplasia and Male Germ Cell Death , 1995, Science.

[33]  G. Inman,et al.  DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. , 1995, The EMBO journal.

[34]  A. Gronenborn,et al.  Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  E. Shaulian,et al.  Induction of apoptosis in HeLa cells by trans-activation-deficient p53. , 1995, Genes & development.

[36]  D. Haber,et al.  The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. , 1995, Genes & Development.

[37]  A. Levine,et al.  Essential role for p53-mediated transcription in E1A-induced apoptosis. , 1995, Genes & development.

[38]  Stephen J. Elledge,et al.  Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.

[39]  A. Neri,et al.  Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. , 1995, Cancer research.

[40]  C. Prives,et al.  Increased and altered DNA binding of human p53 by S and G2/M but not Gl cyclin-dependent kinases , 1995, Nature.

[41]  J. Roth,et al.  Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression , 1995, Molecular and cellular biology.

[42]  A. Levine,et al.  Human TAFII31 protein is a transcriptional coactivator of the p53 protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  V. Rotter,et al.  The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes. , 1995, Oncogene.

[44]  M. Kastan,et al.  Growth factor modulation of p53-mediated growth arrest versus apoptosis. , 1995, Genes & development.

[45]  Tony Pawson,et al.  Protein modules and signalling networks , 1995, Nature.

[46]  E. White,et al.  Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein , 1995, Molecular and cellular biology.

[47]  D. Baltimore,et al.  Modular binding domains in signal transduction proteins , 1995, Cell.

[48]  R. Tjian,et al.  p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. , 1995, Science.

[49]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[50]  N. Hay,et al.  Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. , 1994, Genes & development.

[51]  T. Shenk,et al.  Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R Montesano,et al.  Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.

[53]  M. Karin,et al.  p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes , 1994, Nature.

[54]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[55]  E. May,et al.  Induction of apoptosis by transiently transfected metabolically stable wt p53 in transformed cell lines. , 1994, Cell death and differentiation.

[56]  C. Delphin,et al.  Characterization of baculovirus recombinant wild-type p53 , 1994 .

[57]  S. Deb,et al.  Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. , 1994, Oncogene.

[58]  Hongtao Yu,et al.  Structural basis for the binding of proline-rich peptides to SH3 domains , 1994, Cell.

[59]  Yi-Song Wang,et al.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. , 1994, Cancer research.

[60]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[61]  M. Oren,et al.  Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. , 1993, Oncogene.

[62]  C. Pabo,et al.  The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.

[63]  X. Chen,et al.  A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. , 1993, Genes & development.

[64]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[65]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[66]  L. Donehower,et al.  The tumore suppressor p53 , 1993 .

[67]  A. Levine,et al.  A comparison of the biological activities of wild‐type and mutant p53 , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[68]  J. Pipas,et al.  Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53 , 1993, Nature.

[69]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[70]  A. Braithwaite,et al.  Wild-type mouse p53 down-regulates transcription from different virus enhancer/promoters. , 1993, Oncogene.

[71]  G. Zambetti,et al.  Wild-type p53 binds to the TATA-binding protein and represses transcription. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[72]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[73]  B. Seizinger,et al.  Repression of the basal c-fos promoter by wild-type p53. , 1992, Nucleic acids research.

[74]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[75]  J. Shay,et al.  A transcriptionally active DNA-binding site for human p53 protein complexes , 1992, Molecular and cellular biology.

[76]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[77]  M. Yaniv,et al.  Wild-type p53 can down-modulate the activity of various promoters. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[78]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[79]  I. Verma,et al.  Identification of a transcriptional enhancer element upstream from the proto-oncogene fos. , 1985, Science.

[80]  L. Bracco,et al.  CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. , 1998, The Journal of clinical investigation.

[81]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[82]  C. Delphin,et al.  Characterization of baculovirus recombinant wild-type p53. Dimerization of p53 is required for high-affinity DNA binding and cysteine oxidation inhibits p53 DNA binding. , 1994, European journal of biochemistry.

[83]  L. Donehower,et al.  The tumor suppressor p53. , 1993, Biochimica et biophysica acta.